Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. TTAN
2. BRZE
3. CHYM
4. USO
5. QCOM
6. IRT
7. ASO
8. SPY
9. EVMN
10. AAPL

Go back to Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada
(NYSE: OGN) Delayed: 13.73 -0.02 (0.15%)
Previous Close $13.75    52 Week High $8.00 
Open $13.78    52 Week Low $8.00 
Day High $13.78    P/E N/A 
Day Low $13.73    EPS $0.00 
Volume 430,844